E
Neumora Therapeutics, Inc. NMRA
$1.28 -$0.12-8.57%
Recommendation
Sell
Prev Close
$1.40
Volume
914,584
Avg Vol (90D)
2,510,083
Market Cap
$226.77M
Dividend & Yield
--
52-Week Range
$1.26 - $17.19
P/E (TTM)
--
EPS (TTM)
-$1.53
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. ...
3/14/2025 - GuruFocus
Class Action Filed Against Neumora Therapeutics, Inc. ...
3/13/2025 - GuruFocus
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
3/13/2025 - PR Newswire
Shareholders that lost money on Neumora Therapeutics, Inc. ...
3/13/2025 - GuruFocus
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
3/13/2025 - PR Newswire
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. ( Neumora or the Company ) (NASDAQ: NMRA) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
3/12/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NMRA
3/11/2025 - PR Newswire
NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora ...
3/11/2025 - GuruFocus
NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation
3/11/2025 - PR Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. ...
3/10/2025 - GuruFocus
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm
3/10/2025 - PR Newswire
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. ...
3/10/2025 - GuruFocus
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ...
3/10/2025 - GuruFocus
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform
3/10/2025 - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by William Blair to Market Perform
3/10/2025 - MarketBeat
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
3/10/2025 - Globe Newswire
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...
3/10/2025 - GuruFocus
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRA
3/10/2025 - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. ...
3/9/2025 - GuruFocus
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Neutral Rating by Guggenheim
3/8/2025 - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Cut to Hold at Stifel Nicolaus
3/8/2025 - MarketBeat
Candriam S.C.A. Sells 105,217 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA)
3/8/2025 - Ticker Report
Neumora Therapeutics downgraded to Market Perform from Outperform at William Blair
3/7/2025 - TipRanks Financial Blog
William Blair gets more bearish on Neumora Therapeutics, downgrades shares
3/7/2025 - The Fly
William Blair downgrades Neumora Therapeutics, Inc. (NMRA) to a Hold
3/7/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$262.83M
EBIT (TTM)
-$263.46M
Net Income (TTM)
-$243.79M
Balance Sheet
Total Assets (Q)
$316.97M
Total Debt (Q)
$1.85M
Total Liabilities (Q)
$29.91M
Book Value Per Share (Q)
$1.78
Cash Flow
Cash from Operations (TTM)
-$182.94M
Cash from Investing (TTM)
-$70.56M
Cash from Financing (TTM)
$21.60M
Net Change in Cash (TTM)
-$231.89M
Filings
Filing Date
Monday, March 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-10.49%
30-Day Total Return
-33.33%
60-Day Total Return
-87.60%
90-Day Total Return
-88.82%
Year to Date Total Return
-35.03%
1-Year Total Return
-91.54%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Mar 11, 2025 - $1.26
52-week High
Oct 18, 2024 - $17.19
Valuation
Market Cap
$226.77M - Micro Cap
Enterprise Value
-$78.95M
Price/Sales (TTM)
--
Price/Book (Q)
0.79
Dividends and Shares
Shares Outstanding
160.98M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.neumoratx.com
Phone Number
857 760 0900
Address
490 Arsenal Way
Watertown, MA 02472
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings